如何治疗继发性急性髓系白血病
继发性急性髓系白血病(sAML)包括骨髓增生异常相关AML、骨髓增殖性肿瘤急变期和治疗相关AML,约占新诊断AML的25%~30%,多为不良风险表型,标准治疗下多数患者结局欠佳,且常被临床试验排除,亟需新疗法。本文通过多个病例展示新命名与分类,并给出各临床场景的治疗策略及现有治疗手段的挑战。
要点
- sAML包括骨髓增生异常相关AML、骨髓增殖性肿瘤急变期和治疗相关AML三类,多为不良风险表型。
- sAML约占新诊断AML的25%~30%,发病率随人口老龄化和DNA损伤剂使用而上升。
- 2017年以来获批的许多AML新药对sAML不适用、疗效有限或未在sAML中研究,患者临床试验代表性不足。
核心结论
- sAML包含多种具有不同临床和生物学特征的疾病实体,多数患者接受标准治疗结局欠佳。
- 这些患者临床试验代表性不足,亟需新的治疗选择。
研究设计与样本
- 本文为「如何治疗」类综述,通过多个病例展示sAML的新命名与分类,并给出各临床场景的治疗策略。
主要发现
- sAML约占所有新诊断AML的25%~30%。
- sAML包含AML(骨髓增生异常相关)、骨髓增殖性肿瘤急变期和AML(细胞毒治疗后)三类。
- 2017年以来获批的许多新型药物对sAML不适用(缺乏可靶向突变)、疗效有限或未在这些特定实体中研究。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Secondary acute myeloid leukemia (sAML) has traditionally been used to designate any AML disease arising from an antecedent hematologic disorder or after prior cytotoxic or radiation therapy. We now know sAML comprises multiple disease entities with distinct clinical and biological features: AML, myelodysplastic related; myeloproliferative neoplasm-blast phase; and AML post-cytotoxic therapy. These entities largely represent adverse-risk phenotypes with the majority of patients experiencing suboptimal outcomes with standard therapeutic options. Given the aging general population and the increased life span of individuals receiving DNA-damaging agents for other medical conditions, the incidence of these diseases is steadily rising and now comprise ∼25% to 30% of all new AML diagnoses. Despite the plethora of novel agents approved for AML since 2017, many either are not applicable to sAML (ie, lacking a targetable mutation), have limited efficacy, or have not been studied in these specific entities. Furthermore, these patients are underrepresented in clinical trials, and novel therapeutic options are critically needed. Here, we present multiple patient cases exemplifying the new nomenclature and classification of the diseases comprising sAML and highlighting their diverse presentations. We provide our therapeutic approach for each clinical scenario and discuss the challenges of treatment with the currently available armamentarium.
引用
- Green SD, Wang ES. How I treat secondary acute myeloid leukemia. Blood. 2025. PMID: 39356870. doi:10.1182/blood.2024024011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。